- Privacy Concerns: As awareness of data privacy issues has grown, some potential customers have become wary of sharing their genetic information with private companies.
These factors have culminated in a stark financial reality: 23andMe has yet to turn a profit since going public. The company's stock price has plummeted, with its market value dropping by over 99% from its peak. This financial decline has forced the company to reevaluate its strategies and explore new avenues for monetization.